Achiko signs licensing deal with Regenacellx.sl to commercialise breakthrough Covid-19 testing technology and to further expand its platform

Zurich, 2 July 2020 - Achiko AG (ACHI:SWX), a Swiss FinTech company listed on the SIX Swiss Exchange, announces the licensing of a Covid-19 testing technology developed by Regenacellx.sl. The company plans to take it through clinical trials and commercialise the technology to apply it in conjunction with Teman Sehat, the company's pandemic management platform.

Regenacellx.sl's new Covid-19 test uses advanced DNA aptamer technology, allowing for more accurate results and making it more accessible, faster and significantly cheaper than existing Polymerase chain reaction (PCR) or serological tests. PCR testing suffers from limited accuracy while incurring high costs, and serological tests only indicate an infection in the past.

Achiko has signed partnerships to accelerate the development and commercialisation of the new test kit employing Regenacellx.sl's aptamer technology. Commercial terms with Regenacellx.sl will be finalised by the end of July 2020 and indicatively will give Achiko an exclusive license to the technology and foresee royalty payments to Regenacellx.sl of 5% on gross sales net of hardware costs for an assay reader.

Achiko plans to leverage its Covid-19 test results capture and tracing application, Teman Sehat, with the new test kit, to help bring together a powerful combination of tools to help governments and health authorities combat Covid-19 and potential future pandemics more effectively.

Achiko also intends to extend its Teman Sehat platform to add additional telehealth capabilities in order to help more people to stay healthy and access affordable healthcare options.

Looking beyond the current Covid-19 crisis, Achiko and its partners are investigating other potential uses for the technology, including expanding testing to other pathogens and diseases such as the recently discovered swine flu strain.

About Achiko
Established in 2018, Achiko AG (ISIN CH0522213468) is a platform company listed on the SIX Swiss Stock Exchange (ACHI:SWX) which owns and operates technologies that enable consumers to Pay, offers consumers Things to Do, and provides Reasons to Stay through a range of engaging social features. Social and gaming features will be added to the platform beginning in Q3 and Q4 of 2020.

By refining its technology and operations stack in Indonesia first with subsequent expansion to other countries, the company then aims to deliver services across a range of industry verticals such as Game Payments, Buy Now / Pay Later, ECommerce Services and others directly and indirectly.

Achiko has significant shareholders such as MNC Group, the largest media company in Southeast Asia. Its shareholder base also includes MOX, China's largest venture capital company focussing exclusively on the mobile sector and one of the three largest global VC companies in this field.

Further information can be found at https://investor.achiko.com.

Press Contact:

Germany and Austria
Axel Mühlhaus/ Dr. Sönke Knop
edicto GmbH
E: achiko@edicto.de
T: +49 69 90 55 05-51

Switzerland
Marcus Balogh
Farner Consulting Ltd.
E: achiko@farner.ch
T: +41 44 266 67 67

Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Achiko Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Achiko Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Achiko Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.